#	Pagina
attuale pagina	/open-h2020/projects/194744/index.html

Opendata, web and dolomites

BMEVLP

Biomarkers for clinical assessment of lungs intended for transplantation

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

BMEVLP project word cloud

Explore the words cloud of the BMEVLP project. It provides you a very rough idea of what is the project "BMEVLP" about.

relevance validity discarded ex waiting true technique establishing donated customer generates subjective broaden quality otherwise suffering perfusion commercialize prior market introducing standard accepted lung 60 equivalent hospitals least vivo meur evlp performed carefully clinicians 5000 clinically biomarker company outcomes organs critically 300 fulfill diseases ill solutions select 15 lists stage validated option acute disseminate received rate income comfortable patients internationally metrics clinical optimal assessing transplanted companies transplantation biomarkers device catalyze tools receive scientists 18 function receiving significantly revenue portfolio 1250 transplantations lungs centers 80 xvivo confirm 25 therapeutic

Project "BMEVLP" data sheet

The following table provides information about the project.

Coordinator	XVIVO PERFUSION AKTIEBOLAG Organization address address: Mässans Gata 10 city: GOTEBORG postcode: 400 14 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	http://www.xvivoperfusion.com/about/research-development/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2014
Duration (year-month-day)	from 2014-11-01 to 2015-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	XVIVO PERFUSION AKTIEBOLAG XVIVO PERFUSION AKTIEBOLAG Organization address address: Mässans Gata 10 city: GOTEBORG postcode: 400 14 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (GOTEBORG)	coordinator	50˙000.00

Map

Project objective

Lung transplantation is the only therapeutic option for selected patients suffering from end-stage lung diseases. 80% of all donated lungs are not used for transplantation. The main reason is uncertainty of the function and quality of the lung.

Ex vivo lung perfusion (EVLP) is a technique used to assess quality of lungs prior to transplantation. In collaboration with leading clinical scientists, XVIVO has developed solutions and systems for EVLP. EVLP has recently become internationally clinically accepted. More than 300 patients have received transplanted lungs that would otherwise not have been used. Centers establishing a clinical program for EVLP increase the number of lung transplantations significantly. Clinical outcomes are at least equivalent to outcomes for patients receiving standard lungs. However, in order to disseminate the EVLP technique to a broader range of hospitals, it is necessary to offer objective metrics assessing lung function in addition to the subjective assessment methods used today.

Exploitation of EVLP has an impact for XVIVO. Each EVLP generates an income of about €15 000. Today about 5000 lung transplantations are performed each year. If we can reach 25% increase, it would contribute to a revenue increase of at least 18 MEUR. It also means that 1250 critically ill patients on the waiting lists will receive new lungs. The true potential is to increase the utilization rate of donated lungs to 40-60%. The project aims to carefully select optimal biomarkers in phase 1 and confirm validity and clinical relevance in phase 2 through a clinical study. By introducing new biomarkers, XVIVO will be able to commercialize a device that will broaden the company´s product portfolio and fulfill the customer need for validated tools making clinicians more comfortable to use donated organs that are being discarded today. The project will be performed in collaboration with identified biomarker companies and thus also catalyze their access to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BMEVLP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BMEVLP" are provided by the European Opendata Portal: CORDIS opendata.